Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “TEVA PHARMACEUTICALS AUSTRALIA PTY LTD”

15 pharma patents match "TEVA PHARMACEUTICALS AUSTRALIA PTY LTD" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 15
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 15 pharmaceutical patents matching "TEVA PHARMACEUTICALS AUSTRALIA PTY LTD" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

15 results for “TEVA PHARMACEUTICALS AUSTRALIA PTY LTD” · 30,257 patents in full index Clear search

  1. US 12258401

    Anti-CD47 combination therapy

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  2. US 11618784

    Anti-CD47 combination therapy

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Apr 4, 2023 · Expires Mar 30, 2043

    granted
  3. US 11319356

    Interferon alpha 2B variants

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted May 3, 2022 · Expires Apr 28, 2042

    granted
  4. US 11253591

    Combination of lenalidomide and polypeptide construct, and uses thereof

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  5. US 11117975

    Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted
  6. US 10981986

    Fusions of antibodies to CD38 and attenuated interferon alpha

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  7. US 10822422

    Antibodies against TL1a and uses thereof

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Nov 3, 2020 · Expires Oct 29, 2040

    granted
  8. US 10544199

    Interferon alpha 2B variants

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Jan 28, 2020 · Expires Jan 23, 2040

    granted
  9. US 9963515

    Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted May 8, 2018 · Expires May 3, 2038

    granted
  10. US 9636334

    Combination of lenalidomide and polypeptide construct, and uses thereof

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted May 2, 2017 · Expires Apr 27, 2037

    granted
  11. US 9611322

    Fusions of antibodies to CD38 and attenuated interferon alpha

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Apr 4, 2017 · Expires Mar 30, 2037

    granted
  12. US 9505826

    Modified antibody with improved half-life

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Nov 29, 2016 · Expires Nov 24, 2036

    granted
  13. US 9127057

    Anti-IL-23 heterodimer specific antibodies

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Sep 8, 2015 · Expires Sep 3, 2035

    granted
  14. US 8932588

    Treatment of cancer involving mutated KRAS or BRAF genes

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Jan 13, 2015 · Expires Jan 8, 2035

    granted
  15. US 8901279

    Humanized antibodies with anti-tumor activity

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Dec 2, 2014 · Expires Nov 27, 2034

    granted